Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Iron phosphate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    37 result(s) found for: Iron phosphate. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2017-003439-12 Sponsor Protocol Number: TMP-0916_03 Start Date*: 2018-02-19
    Sponsor Name:Fraunhofer Gesellschaft for its Institute Fraunhofer für Translationale Medizin und Pharmakologie (ITMP)
    Full Title: Safety and efficacy of postoperative i.v. iron substitution with Polyglucoferron compared to Ferric Carboxymaltose and oral iron in patients with diagnosed iron deficiency who develop anaemia pre- ...
    Medical condition: pre-operative iron deficiency in patients with planned elective surgery and pre-/post-operative iron deficiency anamia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10022974 Iron deficiency anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001518-25 Sponsor Protocol Number: P-Monofer-IDA-02 Start Date*: 2014-11-21
    Sponsor Name:Pharmacosmos A/S
    Full Title: A Phase III, Randomised, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) against Placebo in Subjects with Iron Deficiency Anaemia and who are Intolerant or Unrespon...
    Medical condition: Subjects with iron deficiency anaemia (IDA) caused by different aetiologies such as abnormal uterine bleeding, gastrointestinal diseases (e.g. inflammatory bowel disease), cancer, preoperative anae...
    Disease: Version SOC Term Classification Code Term Level
    17.1 10005329 - Blood and lymphatic system disorders 10022972 Iron deficiency anaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001529-28 Sponsor Protocol Number: P-Monofer-BD-02 Start Date*: 2012-06-13
    Sponsor Name:Pharmacosmos A/S
    Full Title: A Randomized, Prospective, Double-Blind, Comparative Placebo-Controlled Study of Intravenous Iron Isomaltoside 1000 (Monofer®) administered by Infusions to Iron-Deficient Blood Donors
    Medical condition: Female first-time bloddonors with iron deficiency
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004851 10022974 Iron deficiency anemia LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-003121-94 Sponsor Protocol Number: P-Monofer-IBD-02 Start Date*: 2011-12-14
    Sponsor Name:Pharmacosmos A/S
    Full Title: A Prospective, Non-controlled, Safety Study of Intravenous Iron Isomaltoside 1000 (Monofer®) administered by a High Dosing Regimen in Subjects with Inflammatory Bowel Disease (PROMISE)
    Medical condition: Inflammatory Bowel Disease (IBD)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10002062 Anaemia iron deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-004370-26 Sponsor Protocol Number: R2451 Start Date*: 2020-02-14
    Sponsor Name:Hull University Teaching Hospitals NHS Trust
    Full Title: Exploratory single centre prospective 12-week comparative double blinded randomised trial of the impact of high-dose iron isomaltoside vs iron carboxymaltose on measures of FGF23, bone metabolism a...
    Medical condition: Iron deficiency anaemia associated with Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    21.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    20.0 10005329 - Blood and lymphatic system disorders 10066763 Chronic iron deficiency anaemia LLT
    20.0 10005329 - Blood and lymphatic system disorders 10022972 Iron deficiency anaemia PT
    20.0 10005329 - Blood and lymphatic system disorders 10055738 Iron deficiency anaemia, unspecified LLT
    20.1 10022891 - Investigations 10072681 Fibroblast growth factor 23 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-004147-37 Sponsor Protocol Number: 16-047 Start Date*: 2017-01-31
    Sponsor Name:Center for Translational & Clinical Research Aachen (CTC-A)
    Full Title: Intravenous iron in patients with heart failure and reduced ejection fraction (HFREF) plus iron deficiency: Effects upon phosphate and FGF23 metabolism
    Medical condition: Systolic heart failure (heart failure with reduced ejection fraction, HFREF) + iron deficiency with serum ferritin <100 μg/l or 100 – 299 μg/L when transferrin saturation (TSAT) is <20%
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002096-26 Sponsor Protocol Number: MV-3-2017 Start Date*: 2017-08-24
    Sponsor Name:Universitetsklinik for Nyresygdomme og Blodtryksforhøjelse, Regionshospitalet Holstebro; Hospitalsenheden Vest
    Full Title: Investigate the differences between treating Chronic Kidney Disease - Mineral and Bone Disorder with an iron-containing phosphate binder or a calcium-containing phosphate binder in dialysis patients.
    Medical condition: Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD), especially bone metabolism and blood vessel calcification
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10027425 Metabolic bone disorders HLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10078095 Chronic kidney disease-mineral and bone disorder PT
    20.0 100000004869 10012347 Dependence on renal dialysis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002452-87 Sponsor Protocol Number: P-Monofer-IBD-03 Start Date*: 2017-09-11
    Sponsor Name:Pharmacosmos A/S
    Full Title: A randomized, double-blinded, comparative trial comparing the incidence of hypophosphatemia in relation to repeated treatment courses of iron isomaltoside and ferric carboxymaltose in subjects with...
    Medical condition: Iron deficiency anemia in subject with inflammatory bowel disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    20.0 10005329 - Blood and lymphatic system disorders 10079322 Anaemia of chronic inflammation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003819-56 Sponsor Protocol Number: 26193789 Start Date*: 2020-06-12
    Sponsor Name:Centre for Surgical Science
    Full Title: Effects of intravenous administered iron in non-anemic iron deficient patients with colorectal cancer. A double blinded clinical randomized trial.
    Medical condition: Iron-deficiency in colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009944 Colon cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038038 Rectal cancer PT
    20.0 10027433 - Metabolism and nutrition disorders 10022970 Iron deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-004729-41 Sponsor Protocol Number: ACT 401 Start Date*: 2009-10-27
    Sponsor Name:INEOS Healthcare Limited
    Full Title: An open, randomized, controlled, parallel group, Phase III study to investigate the safety and efficacy of fermagate and lanthanum carbonate together with a randomized placebo controlled double bli...
    Medical condition: Hyperphosphatemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004730-25 Sponsor Protocol Number: ACT 402 Start Date*: 2009-05-27
    Sponsor Name:INEOS Healthcare Limited
    Full Title: An open, randomised, controlled, parallel group, Phase III study to investigate the safety and efficacy of fermagate and sevelamer hydrochloride in haemodialysis patients with hyperphosphataemia.
    Medical condition: Hyperphosphataemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020711 Hyperphosphataemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) IT (Prematurely Ended) BE (Completed) GB (Prematurely Ended) HU (Prematurely Ended) EE (Prematurely Ended) LT (Completed) BG (Prematurely Ended) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-000831-41 Sponsor Protocol Number: AMAG-FER-IDA-304 Start Date*: 2016-06-09
    Sponsor Name:AMAG Pharmaceuticals, Inc.
    Full Title: A Phase III, Randomized, Multicenter, Double-Blind, Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)
    Medical condition: Iron deficiency anemia (IDA)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004851 10022975 Iron deficiency anemia secondary to blood loss (chronic) LLT
    18.1 100000004851 10022976 Iron deficiency anemia secondary to inadequate dietary iron intake LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) LV (Completed) LT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-002571-18 Sponsor Protocol Number: 170KG18 Start Date*: 2019-07-22
    Sponsor Name:University Medical Center Groningen
    Full Title: EFFECT OF FERRIC CARBOXYMALTOSE ON EXERCISE CAPACITY AFTER KIDNEY TRANSPLANTATION: A MULTICENTER RANDOMIZED CONTROLLED TRIAL
    Medical condition: Iron deficiency in kidney transplant recipients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10022971 Iron deficiencies HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005746-39 Sponsor Protocol Number: IH 001 (ACT 2) Start Date*: 2006-02-21
    Sponsor Name:Ineos Healthcare Ltd
    Full Title: A multicentre Phase II study with Alpharen™: an open-label, dose-ranging phase followed by a placebo-controlled, double-blind, parallel-group comparison in haemodialysis subjects with hyperphosphat...
    Medical condition: Hyperphosphataemia in haemodialysis subjects
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000776-29 Sponsor Protocol Number: P-Monofer-PREG-01 Start Date*: 2017-05-03
    Sponsor Name:Pharmacosmos A/S
    Full Title: Intravenous iron isomaltoside versus oral iron supplementation for treatment of iron deficiency in pregnancy: a randomised, comparative, open-label trial
    Medical condition: iron deficiency in pregnant women
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    20.0 10005329 - Blood and lymphatic system disorders 10002041 Anaemia complicating pregnancy, childbirth, or the puerperium LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-003240-20 Sponsor Protocol Number: 16-058 Start Date*: 2017-10-12
    Sponsor Name:RWTH Aachen, represented by the rector, himself represented by the dean of the Medical Faculty
    Full Title: Velphoro and impact on the oral cavity and gut microbiome
    Medical condition: Hyperphosphatemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002095-10 Sponsor Protocol Number: MV-2-2017 Start Date*: 2017-09-13
    Sponsor Name:Universitetsklinik for Nyresygdomme og Blodtryksforhøjelse, Regionshospitalet Holstebro; Hospitalsenheden Vest
    Full Title: Investigate the differences between treating Chronic Kidney Disease - Mineral and Bone Disorder with an iron-containing phosphate binder or a calcium-containing phosphate binder in Chronic Kidney D...
    Medical condition: Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD), especially bone metabolism and blood vessel calcification
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10076411 Chronic kidney disease stage 4 LLT
    20.0 100000004857 10076412 Chronic kidney disease stage 5 LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10027425 Metabolic bone disorders HLT
    20.0 100000004857 10076410 Chronic kidney disease stage 3 LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10078095 Chronic kidney disease-mineral and bone disorder PT
    20.0 100000004861 10020712 Hyperphosphatemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-004186-21 Sponsor Protocol Number: VICTORID_01 Start Date*: 2023-09-14
    Sponsor Name:Dipartimento di Medicina-DIMED, università di Padova
    Full Title: Beneficial effects of vitamin D combined with oral iron supplementation in patients with chronic heart failure and iron deficiency (VICTORID-HF TRIAL)
    Medical condition: Chronic heart failure; iron deficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10019284 Heart failure, congestive LLT
    20.0 10007541 - Cardiac disorders 10007558 Cardiac failure chronic PT
    20.1 10007541 - Cardiac disorders 10064081 Heart failure NYHA class III LLT
    20.1 10007541 - Cardiac disorders 10064080 Heart failure NYHA class II LLT
    24.0 100000004861 10060496 Hyposideremia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-005644-26 Sponsor Protocol Number: 1.2012 Start Date*: 2014-12-23
    Sponsor Name:Atrium Medical Centre
    Full Title: Administration of intranvenous ferric carboxymaltose to children with IBD
    Medical condition: Anemia in children with Inflammatory Bowel Disease (IBD)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004735-30 Sponsor Protocol Number: IH 003 Start Date*: 2006-11-20
    Sponsor Name:Ineos Healthcare Ltd
    Full Title: An open label, dose-ranging study to establish the tolerability of Alpharen™ in haemodialysis subjects with hyperphosphataemia.
    Medical condition: Hyperphosphataemia in haemodialysis subjects
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020711 Hyperphosphataemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 22 12:47:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA